Publications

Hodgkin Lymphoma

Critical Reading

1. German Hodgkin Study Group HD10

2. German Hodgkin Study Group HD11

3. EORTC-LYSA-FIL H10

4. UK RAPID Trial

5. RATHL Trial

Supplemental Reading

1. German Hodgkin Study Group HD13

2. German Hodgkin Study Group Experience in Stage I LP-HL

3. German Hodgkin Study Group Long-Term Follow-Up of HD7, HD8, HD10, HD11

4. Reduced Mortality Risk in the Recent Era in ES-HL Patients Treated with RT with or without Chemo

5. IFRT for Patients in PR after Chemo for Advanced HL

6. New Definition of Bulk in HL in CT Era

7. Reduced Mortality Risk in ES-HL Patients Treated with RT

8. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed HL

9. Brentuximab Vedotin with Chemotherapy for Stage III or IV HL

Non-Hodgkin Lymphoma

Critical Reading

1. Reduced Dose RT for Local Control in NHL

2. FORT Trial

3. RICOVER-60 NoRTh

Supplemental Reading

DLBCL

1. DLBCL ACR Appropriateness Criteria 

2. Re-examining the Role of RT for DLBCL in the Modern Era

3. SWOG 8516: CHOP vs. Other Intensive Chemotherapy Regimens

4. SWOG S8736 CHOP3 + RT vs. CHOP8

5. LNH-98.5: CHOP vs R-CHOP 

6. MInT: CHOP vs. R-CHOP

7. IFRT vs INRT as Consolidation for DLBCL 

8. LYSA trial: R-CHOP +/- RT

9. Consolidative RT after R-CHOP: MDACC Experience

10. Skeletal DLBCL 

11. NCDB: Use of RT for DLBCL

12. SEER: Use of RT for DLBCL

13. PARMA: +/- ASCT for Relapsed NHL

14. RT for Relapsed/Refractory DLBCL 

15. DLBCL Subtypes by Gene Expression Profiling 

16. Hans Algorithm: Classification of DLBCL Subtypes by Immunohistochemistry

17. Reduction of the treated volume to INRT as part of CMT for early stage aggressive NHL

PMBCL

1. NCI Phase 2 Trial: Dose-Adjusted R-EPOCH for PMBCL

2. IELSG26: Response Assessment by PET in PMBCL

3. Improved Survival with Combined Modality for PMBCL

Primary CNS Lymphoma

1. IELSG32 Phase 2 Trial: Consolidative WBRT vs. ASCT

2. R-MPV + reduced dose WBRT: MSKCC Experience

Follicular Lymphoma

1. LymphoCare: Patterns of Care for FL in the USA

2. TROG 99.03: IFRT +/- R-CVP for FL

3. Salvage Treatment and Survival for Relapsed FL Following Primary RT: Collaborative ILROG Study

4. Definitive RT for localized FL staged by 18F-FDG PET-CT: Collaborative ILROG Study

Marginal Zone Lymphoma

1. Gastric MALT Treated with RT Alone: MSKCC Experience

2. Orbital MALT treated with low-dose RT: Stanford Experience

3. Long-term outcome of early-stage extranodal marginal zone lymphoma: MSKCC Experience

4. Long-term outcome of early-stage extranodal marginal zone lymphoma after RT: MSKCC Experience

Mantle Cell Lymphoma

1. Early-stage MCL: A Retrospective Analysis from ILROG

2. RT as an Effective Modality for MCL

3. 4Gy as an Effective Treatment of MCL

Cutaneous Lymphoma

1. Efficacy of 12 Gy TSEB 

2. RT for Low-grade Cutaneous B-cell Lymphoma

Solitary Plasmacytoma

1. Rare Cancer Network Study: Solitary Plasmacytoma of Bone

2. Solitary Plasmacytoma: MDACC Experience

Leukemia

1. Chloroma: MSKCC Experience

2.  Cranial RT for CNS+ AML: University of Washington Experience

3. Craniospinal Irradiation for CNS+ Leukemia: MDACC Experience

4.  TBI Review 

RT Techniques

1. IMRT Butterfly Technique for Mediastinal Lymphoma

2. Cardiac Atlas

Long-Term Toxicity

1. Dose-response Relationship for Coronary Heart Disease in HL Survivors

2. Secondary Breast Cancer Risk by RT Volume in HL Survivors 

3. 2013 - Prospective study of the efficacy of breast MRI and mammographic screening in survivors of HL

Imaging

1. Lugano Classification

2. Prospective Study of PET with CT Co-registration for RT Planning

Health Policy

1. 2016 - Are Advanced RT Techniques Necessary for HL?

Editorials

1. 2018 - Early-Stage FL: What Is the Preferred Treatment Strategy?

2. 2018 - Progress in the Treatment of Hodgkin's Lymphoma

3. 2018 - Balancing Risk and Benefit in Early-Stage cHL

4. 2016 - Re-examining the Role of RT for DLBCL in the Modern Era

5. 2014 - Limited-Stage Hodgkin Lymphoma: Managing Uncertainty

6. 2014 - RT for Indolent Lymphomas: How Much is Enough?

Reviews

1. 2020 - Hematologic Malignancies (Y Tseng, A Ng)